The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
The deal will enable the Australian firm to distribute its diagnostic tests in the United Arab Emirates, Saudi Arabia, Bahrain, Qatar, and Oman.
UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.
The Australian maker of multiplexed molecular diagnostics tests has now partnered with distributors in Germany, Austria, Sweden, and Turkey.
The test can detect resistance to two of the most commonly prescribed antibiotics used to treat strep throat, and could potentially be adapted for point-of-care use.
The company said it intends to use the proceeds of the placement to continue work on its microfluidic PCR-based platform for pathogen detection.
The test will leverage next-generation sequencing to sequence PCR amplicons of the UL54 and UL97 genes in which drug resistance with CMV has been associated.
The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.
The test is designed to identify and differentiate between Zika, dengue, and chikungunya in serum samples, even in the presence of more than one target.
In an SEC document, the company said net proceeds are expected to be $5.8 million and will be used to support an anticipated submission to the FDA, among other things.
The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.
The company has been gearing up to submit its Acuitas AMR Gene Panel product to the US Food and Drug Administration for regulatory clearance.
The deals cover the Finnish diagnostic company's Amplidiag and Novodiag lines of infectious disease and antibiotic resistance testing products.
The firm missed the consensus Wall Street estimate on the bottom line, even as its ePlex analyzer Q4 revenues more than doubled year over year to $12.1 million.
The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
Researchers profiled cervical microbe communities in relation to HPV, HIV, and cervical cytology status, identifying microbial shifts in high-grade lesions and HIV-positive cases.
The firms said that HuaSin obtained exclusive rights to develop a fully automated HPV genotyping assay platform that uses Genomica’s technology.
The companies have signed a licensing agreement related to bioinformatics tools to enable antimicrobial resistance research.
Researchers used genomic, transcriptomic, and virulence data on thousands of Streptococcus pyogenes strains to identify features influencing infections.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.